To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Primaquine (or primaquine phosphate) is a medication used in the treatment of malaria and Pneumocystis pneumonia. It is a member of the 8-aminoquinoline group of drugs that includes pamaquine.
Additional recommended knowledge
Primaquine is mainly used to treat the P. vivax or P. ovale malaria. Once the parasite has been eliminated from the bloodstream, the remaining hypnozoites must be removed from the liver and this is done by administering a 14 day course of primaquine (called radical cure).
If primaquine is not administered to patients with proven P. vivax or P. ovale infection, there is a very high likelihood relapse within weeks or months (sometimes years).
When attempting a radical cure, primaquine requires the presence of quinine or chloroquine in order to work. If primaquine is given alone, the cure rate is only 21%. This is why primaquine should always be given with quinine or chloroquine. It is not known if other antimalarials such as mefloquine are likewise able to potentiate the effect of primaquine.
Primaquine is not routinely used to prevent malaria in travellers, and is only used as such when no other alternatives are appropriate. It is not licensed for this use in the U.S. or UK.
Primaquine is also sometimes used presumptively to prevent malaria in people who have gone to areas where P. vivax or P. ovale are endemic (called terminal prophylaxis), but this practise is not common outside of the U.S. and is controversial.
Primaquine is also used in the treatment of Pneumocystis pneumonia, a fungal infection commonly occurring in people with AIDS and, more rarely, in those taking immunosuppressive drugs. To treat PCP effectively it is usually combined with clindamycin.
Side effects of primaquine administration include nausea, vomiting, and stomach cramps. Other known adverse effects that occasionally occur are headache, visual disturbances and intense itching. Primaquine has also been shown to cause Hemolytic anemia in people of African or Mediterranean descent.
Primaquine causes methemoglobinemia in all patients who take it (levels of up to 18% are reported, normal level is <1%), but this seldom causes symptoms and is always self-limiting. Dangerous levels of methemoglobinemia only occur in patients with glucose-6-phosphate dehydrogenase deficiency.
Primaquine should not be administered to anyone with Glucose-6-phosphate dehydrogenase deficiency as there can be a severe reaction with hemolytic anemia. Primaquine is contraindicated in pregnancy, because the G-6-PD status of the fetus will not be unknown. Primaquine should not be given to patients with NADH methemoglobin reductase deficiency.
The packaging label states that primaqine should not be given to patients with systemic lupus erythematosus or rheumatoid arthritis, but the rationale behind this is questionable.
Primaquine doses are always expressed as base, not as salt (15 mg base=26.3 mg phosphate salt).
The FDA licensed dose in the U.S. is 15 mg once daily, but this is not the dose recommended by the CDC for P. vivax; the FDA decision in 1952 to limit the primaquine dose to 15 mg was motivated by the fact that G-6-PD testing was not routinely available, 15 mg was known to be effective against the P. vivax strains found in Korea (in the US, the main use of primaquine at that time was to treat soldiers returning from war), and because 15 mg of primaquine is not likely to cause hemolysis in G-6-PD deficient patients. Primaquine is not licensed in the UK, but is available on a named-patient basis.
The dose of primaquine in primary malaria prophylaxis is 30 mg once daily, starting the day before travel and continuing for 7 days after returning. It needs only to be given for seven days after returning because primaquine is active against liver schizonts (the exoerythrocytic stages) and is therefore a causal prophylactic. In children, the dose is 0.6 mg/kg/day (the maximum daily dose is 30 mg).
Manufacturing and availability
Primaquine was first tested on humans during the Stateville Penitentiary Malaria Study in 1944. Primaquine was licensed for use in the US by the FDA in 1952 and is available as a generic drug from a variety of manufacturers.
Primaquine is not licensed for use in the UK. It is available on a named patient basis only from Durbin or IDIS. Primaquine tablets available in the UK contain 7.5 mg primaquine base (13.2 mg phosphate salt). Primaquine tablets available in the U.S. contain 15 mg base (26.3 mg phosphate salt).
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Primaquine". A list of authors is available in Wikipedia.|